By Scott Kanowsky
Investing.com -- AstraZeneca PLC (LON: AZN ) has signed a $320 million cash and debt deal to acquire bio-technology group Neogene Therapeutics, as the U.K. drugmaker looks to expand its cancer therapy portfolio.
In a statement on Tuesday, AstraZeneca said the transaction will include a $200M initial payment, plus an additional $120M that is partly contingent on hitting certain milestones. The purchase is expected to close in the first quarter of 2023, subject to regulatory clearances.
The Cambridge, U.K.-based company added that the acquisition will not impact its financial guidance for 2022.
AstraZeneca said the move aims to harness Neogene's expertise in the development and manufacturing of so-called T-cell receptor therapies that offer a new approach to treating cancer patients with solid tumors.
“This acquisition represents a unique opportunity to bring innovative science and leading experts in T-cell receptor biology and cell therapy manufacturing together with our internal oncology cell therapy team, unlocking new ways to target cancer," said Susan Galbraith, executive vice president of oncology research and development at AstraZeneca.
"Neogene’s leading TCR discovery capabilities and extensive manufacturing experience complement the cell therapy capability we have built over the last three years and allow us to accelerate the development of potentially curative cell therapies for the benefit of patients.”
Under the terms of the deal, Neogene will operate as a wholly-owned subsidiary of AstraZeneca with operations in the U.S. and the Netherlands.
London-listed shares in AstraZeneca were higher in morning trading on Tuesday.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.